NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

940.05 -9.95 (-1.05%)

27.90% Fall from 52W High

30,739 NSE+BSE Volume

NSE 23 Sep, 2025 3:31 PM (IST)

18,477.9

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

09 Nov 2017

940.05

-1.05%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 10% YoY to | 789 crore (I-direct estimate: | 846 crore) mainly on account of 26% YoY decline in the export business to | 262 crore (I-direct estimate: | 277 crore). Domestic sales increased 6% YoY to | 385 crore (I-direct estimate: | 396 crore) EBITDA margins improved 248 bps YoY to 22.7% (I-direct estimate: 18.0%) mainly due to lower other expenditure. EBITDA increased 1% YoY to | 179 crore vis--vis I-direct estimate of | 152 crore...

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

08 Nov 2017

940.05

-1.05%

Alembic Pharma (2QFY18): Increased costs to weigh on margins. Downgrade to NEUTRAL

Neutral: Alembic Pharmaceuticals Ltd.

Recommendation Target

HDFC Securities

Downgrade to NEUTRAL with a TP of Rs 555 (20x on Sep-19E). Alembic Pharmas (ALPM) top-line declined ~10% YoY in 2QFY18 on a high base of 2QFY17, which included limited competition sales of gAbilify. There was QoQ growth of 23%. The domestic business performance was disappointing, growing only ~6% YoY in spite of the benefits of channel re-stocking. The EBITDA margin surprised positively at ~23%, up 230bps/690bps YoY/QoQ (370bps beat). This was largely driven by operating leverage and a favourable business mix. PAT stood at Rs 1.2bn, up ~82% QoQ.

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

07 Nov 2017

940.05

-1.05%

Margins surprise positively; US biz remains under pressure

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

remained flat sequentially, but as % of sales, it rose by >400bp). PAT increased 2% YoY to INR1.2b (23% beat). Strong recovery in domestic business; US remains under pressure: Domestic business grew 6% YoY, driven by ~10% YoY growth in Specialty business. Top-line growth in domestic market was impacted by treatment of excise duty post GST implementation. On a like-to-like basis, domestic business grew ~13% YoY. International business sales declined 26% YoY. US business declined by ~29% YoY and non-US business by ~13% YoY. We...

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

01 Aug 2017

940.05

-1.05%

Result Updates

Accumulate: Alembic Pharmaceuticals Ltd.

Target

Angel Broking

Alembic Pharma posted marginally lower than expected results for 1QFY2018. In Rupee terms, revenues de-grew by 12.0% yoy to `648cr (`737cr expected) v/s. `737cr in 1QFY2017. International formulation came in at `282cr v/s. `309cr in 1QFY2017, a yoy dip of 8.7%. Indian formulation sales came in at `236cr v/s. `299cr in 1QFY2017, a yoy dip ..

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

26 Jul 2017

940.05

-1.05%

Result Update - Alembic Pharma

Hold: Alembic Pharmaceuticals Ltd.

Axis Direct

Alembic Pharma's (ALPM) Q1FY18 results were below estimates due to 21% YoY decline in India revenue (estimate: 12% YoY decline) on channel destocking ahead of GST rollout. Management expects gradual restocking in the trade channel, and subsequent volume recovery through Q2'18. US sales declined ..

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

21 Jul 2017

940.05

-1.05%

Alembic Pharma (1QFY18): GST disruption. Maintain BUY

Buy: Alembic Pharmaceuticals Ltd.

Target

HDFC Securities

Continuous investments and erosion in gAbilify saleshave led to a correction in the stock. We believe that the business remains attractive at these valuations. Maintain BUY with a TP of Rs 635 (20x Jun-19E). Alembic Pharmas (ALPM) top-line declined ~12% YoY in 1QFY18, with the domestic business plummeting 21% YoY. The EBITDA margin at 15.8% was down 575bps YoY (240bps miss). PAT stood at Rs 667mn, down ~36%YoY. In our view, while 1QFY18 was a weak quarter for ALPM, this was largely expected on account of pre-GST channel de-stocking. Profitability was further impacted by compensation given to dealers for lost input tax credit. The only positive was sequential growth in the US base business (five product launches in 1QFY18).

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

21 Jul 2017

940.05

-1.05%

Alembic Pharmaceuticals

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 12% YoY to | 648 crore (I-direct estimate: | 672 crore) mainly on account of a 21% decline in domestic formulations to | 236 crore on the back of GST transition. Total export sales declined 9% to | 282 crore in line with I-direct estimate EBITDA margins contracted 565 bps YoY to 15.6% (I-direct estimate: 18.0%) due to higher employee cost and R&D; expenses. EBITDA declined 35% YoY to | 101 crore (I-direct estimate: | 121 crore)...

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

23 May 2017, 07:27PM

940.05

-1.05%

Alembic Pharmaceuticals Ltd Q4FY17 results comment

Results Update: Alembic Pharmaceuticals Ltd.

HDFC Securities

Revenue fell by 4.59% to Rs. 741.35 Cr in Q4FY17 when compared to the previous quarter.

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

09 May 2017

940.05

-1.05%

Result Updates

Accumulate: Alembic Pharmaceuticals Ltd.

Angel Broking

Alembic Pharma posted marginally lower than expected results for 4QFY2017. In Rupee terms, revenues grew by 17.8% yoy to `737cr (`770cr expected) v/s `626cr in 4QFY2016. In sales terms, the company posted growth on the back of international formulations, which grew by 44% yoy, while the Indian domestic formulations grew by 6.0% yoy. On th..

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Is Alembic Pharmaceuticals Ltd. worth buying?

239 Votes:

Buy 84.1%

Sell 7.95%

Hold 7.95%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf